parpi olaparib for the targeted treatment of metastatic prostate cancer
Published 3 years ago • 444 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
5:15
rucaparib and olaparib: two new treatments approved for advanced prostate cancer | pcri
-
5:14
olaparib and keytruda for advanced prostate cancer | | learn about clinical trials
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
3:32
treatment options for metastatic prostate cancer
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
3:48
olaparib zytiga for metastatic castrate-resistant prostate cancer | learn about clinical trials
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer
-
1:39
challenges in the field of parpi treatment for mcrpc
-
1:21
combining a parp and pd-l1 inhibitor to treat prostate cancer
-
1:22
dr. hwang on the state of treatment in metastatic prostate cancer
-
3:13
treatment options in metastatic prostate cancer
-
1:00
dr. morgan discusses the impact of parp inhibitors in prostate cancer
-
4:22
the role of radiology in metastatic prostate cancer
-
2:18
#esmo21 highlights on maintenance olaparib in ovarian cancer previously treated with parpi
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
1:34
combination therapies for the treatment of prostate cancer
-
1:38
dr. morgan on olaparib for metastatic castration-resistant prostate cancer
-
3:28
apalutamide and the titan clinical trial
-
8:51
esmo 2020 expert video report on precision medicine in prostate cancer